{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:11:50Z","timestamp":1765260710521,"version":"3.46.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of flumatinib, a second-generation tyrosine kinase inhibitor (TKI), combined with chemotherapy in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and to analyze factors influencing prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, single-center, observational study included 15 newly diagnosed adult Ph+ ALL patients admitted between January 2022 and December 2024. All patients received a flumatinib-based combination chemotherapy regimen (600 mg once daily). The primary outcomes included complete remission (CR) rate, negativity rates for fusion gene and flow cytometry-based minimal residual disease (MRD), progression-free survival (PFS), overall survival (OS), and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 15 patients, 14 achieved hematological complete remission (93.3%). At the end of induction therapy, the fusion gene and flow-MRD negativity rates were 60.0% (9\/15) and 73.3% (11\/15), respectively. By 3 months of treatment, the cumulative negativity rates increased to 80.0% (12\/15) and 86.7% (13\/15), respectively. With a median follow-up of 26 months, the median PFS and OS were 11 months (range: 1\u201360) and 24 months (range: 6\u201360), respectively. Subgroup analysis revealed that two patients with chronic myeloid leukemia in lymphoid blast phase (CML-LBP) had extremely poor outcomes, with median PFS and OS of only 3 months and 7.5 months, respectively. The most common grade 3\u20134 adverse events were hematological toxicities (53.3%), followed by infections and liver function abnormalities. All AEs were manageable with supportive care, and no treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Flumatinib combined with chemotherapy induced high remission rates and deep molecular responses in newly diagnosed Ph+ ALL patients, with a favorable safety profile. However, patients with CML-LBP or high-risk Ph+ ALL had poor treatment responses and outcomes, indicating the need for more aggressive intervention strategies in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1721146","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:13:09Z","timestamp":1765257189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of flumatinib in adults with Ph-positive ALL: a prospective observational study"],"prefix":"10.3389","volume":"15","author":[{"given":"Jianmei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luoming","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11664","article-title":"The biology and therapy of adult acute lymphoblastic leukemia","volume":"98","author":"Faderl","year":"2003","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586","article-title":": First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-636548","article-title":": Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","article-title":"Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges","volume":"12","author":"Soverini","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"126758","DOI":"10.1016\/j.bmcl.2019.126758","article-title":"Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants","volume":"29","author":"Yang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: A phase III, randomized, open-label, multi-center FESTnd study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.htct.2023.12.005","article-title":"Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia","author":"Liu","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1178393","article-title":"Basic and clinical study of efficacy and adverse effects of flumatinib in Ph(+) ALL","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/j.clml.2025.04.010","article-title":": Real-world Efficacy and Safety of Flumatinib as the First-line Treatment in Patients With de novo Philadelphia-positive Acute Lymphoblastic Leukemia","volume":"25","author":"Zhang","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665","article-title":": Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3892\/ol.2021.12920","article-title":"Role of CXCL12, TP53 and CYP1A1 gene polymorphisms in susceptibility to pediatric acute lymphoblastic leukemia","volume":"22","author":"Kampouraki","year":"2021","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"107019","DOI":"10.1016\/j.leukres.2023.107019","article-title":"Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia","volume":"126","author":"Nabil","year":"2023","journal-title":"Leuk Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27708","article-title":"Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","article-title":": Molecular characterization and predictors of relapse in patients with Ph\u2009+\u2009ALL after frontline ponatinib and blinatumomab","volume":"18","author":"Short","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","article-title":"Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia","volume":"37","author":"Senapati","year":"2023","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546371","article-title":": Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study","volume":"16","author":"Wen","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4783","article-title":": ponatinib vs imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"Jama"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1721146\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:13:10Z","timestamp":1765257190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1721146\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1721146"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1721146","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"article-number":"1721146"}}